News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sensus Healthcare Receives FDA Clearance to Treat Keloids With the SRT-100™



5/24/2013 8:53:36 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOCA RATON, Fla.
, May 24, 2013 /PRNewswire/ -- Sensus Healthcare is pleased to announce that it has received clearance from the U.S. Food and Drug Administration to treat Keloids with the SRT-100. The SRT-100 is the leading alternative to surgery in treating Non Melanoma Skin Cancer and now is approved to treat Keloids caused by surgery or injury. Leading Dermatologists and Oncologists have found the SRT-100 superficial radiotherapy system to be an excellent choice for their patients who are not good surgical candidates. Sensus Healthcare has reintroduced superficial radiotherapy (SRT) to the global clinical community as a viable, safe, and cost-effective modality to treat non-melanoma skin cancers and keloids in hospitals and private practice settings.

(Logo: http://photos.prnewswire.com/prnh/20130222/FL64841LOGO )

"Painful and potentially disfiguring keloid scars are very difficult to effectively treat by surgery or other means due to recurrence rates as high as 45 to 100%. Studies show that the use of adjunctive radiation therapy can dramatically reduce the rate of recurrences," stated Mark S. Nestor, MD, PhD of the Center for Cosmetic Enhancement in Aventura, FL.

Dr. Nestor continues to say, "It is very fortunate that the FDA has approved the Sensus SRT-100, the first computerized, state of the art in office SRT device, for the treatment of recurrent keloid scars. Dermatologists now have a safe, effective in office modality available to offer our keloid patients."

"The SRT-100 technology continues to demonstrate its potential as we expand our indications into other areas of treatment. This important indication can be applied to every surgical procedure for those patients susceptible to forming keloids," stated Joe Sardano, President/CEO, Sensus Healthcare.

SRT-100 is an ideal treatment modality for non-melanoma skin cancers and keloids, thanks to its SharpBeam technology, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100 is FDA, CE, Health Canada, and SFDA cleared and is manufactured in the United States of America under the stringent ISO-13485 and GMP quality standards.

About Sensus Healthcare:
Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100 systems are used throughout the world by leading radiation oncologists and dermatologists to bring non-melanoma skin cancer and keloid treatments to more patients in more settings.

Media Contact:
Michelle Verina
Public Relations
561-922-5808 Ext. *100
michelle@sensushealthcare.com

SOURCE Sensus Healthcare



Help employers find you! Check out all the jobs and post your resume.
Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES